Confident Moves Intervention Efficacy Trial: Obesity Care Settings

June 2, 2026 updated by: Seungmin Lee, Iowa State University
The objective of this study is to evaluate the efficacy of the Confident Moves (CM) intervention on device-measured physical activity (PA) and the whole person health index in adults with obesity, compared to standard obesity care alone. Confident Moves (CM) is a web-based physical activity (PA)-promoting research intervention developed by the study team to support adults with obesity. CM is not a medical or clinical treatment; rather, it is designed to promote daily PA through structured, self-paced online learning activities. The intervention has been previously pilot-tested in a feasibility study, which demonstrated its acceptability, safety, and feasibility and informed refinements to study procedures. CM aims to strengthen participants' confidence, knowledge, and behavioral skills related to PA across multiple everyday contexts. The intervention is delivered through a secure, ISU-managed website, with access limited to enrolled participants and authorized research personnel. Only study staff have access to participant data, and data are used solely for research purposes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
348

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 18-64 years
  • Body Mass Index (BMI) ≥ 25 kg/m²
  • Access to a technological device (e.g., computer, smartphone) capable of supporting the online intervention
  • Not currently enrolled in another physical activity (PA) intervention (except standard obesity care programs at participating centers)
  • Willingness to wear a wrist worn accelerometer for two separate 7 day monitoring periods
  • Willingness to respond to study related communications (e.g., email, text, phone call)

Exclusion Criteria:

- Failure to meet one or more of the inclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Standard Care Group
Participants assigned to the standard care group will receive only the obesity centers' standard obesity care program during the data collection period. They will be provided with login credentials to access the CM website for data collection at wave 1 (W1), wave 2 (W2), and wave 3 (W3).
Experimental: CM Group
Participants assigned to the Confident Moves (CM) group also will receive the obesity centers' program and will be provided with 4 weeks of continuous (24-hour) access to the CM intervention during the data collection period. Access to the CM intervention will become available between W1 and W2, and those in this group will be notified via email. They will be encouraged to actively engage with the intervention, including completing at least 26 intervention challenges. They will be provided with login credentials to access the CM website for both the CM intervention and data collection at W1, W2, and W3.
Behavioral: Confident Moves (CM) Intervention
Confident Moves (CM) is a web-based physical activity (PA) intervention designed to integrate with obesity care and support daily PA in adults with obesity. A 2025 feasibility trial supported the development of a future randomized controlled trial and identified areas for refinement. Grounded in social cognitive theory, CM targets self-efficacy through structured learning activities such as games, videos, lectures, and self-reflection, incorporating behavior change techniques like goal setting and action planning. The online program includes seven components addressing multiple PA domains and mindfulness, delivered over 4 weeks with flexible access.
Other Names:
  • Physical Activity Self-efficacy (PAS) Intervention

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
ActiGraph wGT3X-BT
Time Frame: At W1 (Week 1-4) and W3 (Week 13-16)
Device-measured physical activity (PA) will be assessed at W1 and W3 using the ActiGraph wGT3X-BT (Pensacola, FL, USA), a tri-axial research-grade accelerometer. Devices will collect data at 30 Hz and be reintegrated into 60-s epochs. Non-wear will be defined as ≥90 consecutive minutes of zero counts, allowing ≤2 min of nonzero counts if surrounded by ≥30 min of zeros. Data will be considered valid if participants have ≥3 days with ≥10 h/day of wear, no device malfunction, and consistency with logs. Moderate-to-vigorous PA (MVPA) will be defined as ≥3,941 counts/min using wrist-specific vector magnitude cut-points validated in free-living adults.
At W1 (Week 1-4) and W3 (Week 13-16)
Whole Person Health Index (WPHI) scale
Time Frame: At W1 (Week 1-4) and W3 (Week 13-16)
The Whole Person Health Index (WPHI) will be measured at W1 and W3 using a 9-item self-reported scale developed by the National Center for Complementary and Integrative Health, in collaboration with the Centers for Disease Control and Prevention. The WPHI assesses overall health across physical, psychological, and social domains, reflecting a whole person health framework beyond disease-specific outcomes. Items assess general health, quality of life, social/family connections, diet, physical activity, stress management, sleep, meaning/purpose, and ability to manage health, rated on a 5-point Likert scale (1=poor to 5=excellent). The WPHI is validated and used in observational and clinical studies, including the 2025 National Health Interview Survey. Total scores range from 9 to 45, with higher scores indicating better health outcomes.
At W1 (Week 1-4) and W3 (Week 13-16)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Physical Activity Self-Efficacy (PASE) scale
Time Frame: [Time Frame: At W1 (Week 1-4) and W2 (Week 9)]
Physical Activity Self-Efficacy (PASE) will be assessed at W1 and W2 using a 36-item self-reported scale measuring confidence in achieving recommended weekly physical activity (PA). PASE evaluates self-efficacy across four domains: occupational, transport, domestic, and leisure PA. Occupational and leisure domains include moderate- and vigorous-intensity activities, whereas transport and domestic domains include moderate-intensity activities only. Items are rated on a 5-point scale (0 = no confidence to 4 = complete confidence), consistent with standard self-efficacy measures. Total scores range from 0 to 144, with higher scores indicating greater PA self-efficacy.
[Time Frame: At W1 (Week 1-4) and W2 (Week 9)]
Self-Efficacy to Regulate Physical Activity (SERPA) scale
Time Frame: [Time Frame: At W1 (Week 1-4) and W2 (Week 9)]

Self-efficacy to regulate physical activity (SERPA) will be measured at W1 and W2 using a 13-item version of the SERPA scale. This scale will assess participants' confidence in their ability to overcome barriers to sustaining weekly PA. Previous measurement studies of the SERPA scale indicate a two-factor structure reflecting different types of barriers to PA. Items are rated on a five-point self-efficacy scale (0 = no confidence to 4 = complete confidence).

Total scores range from 0 to 52, with higher scores indicating better outcomes.
[Time Frame: At W1 (Week 1-4) and W2 (Week 9)]
Self-Efficacy for Whole Person Health (SE-WPH) scale
Time Frame: [Time Frame: At W1 (Week 1-4) and W2 (Week 9)]
Self-Efficacy for Whole Person Health (SE-WPH) will be measured at W1 and W2 using a newly developed 9-item self-reported scale. The SE-WPH assesses confidence in engaging in and sustaining behaviors that support whole person health across physical, psychological, and social domains, aligned with the Whole Person Health Index (WPHI). Items reflect key areas including overall health and quality of life, social connections, health behaviors (diet, physical activity, sleep, stress), and health self-management. Items are rated on a 5-point scale (0 = no confidence to 4 = complete confidence). Psychometric evaluation (reliability and validity) will be conducted prior to hypothesis testing. Total scores range from 0 to 36, with higher scores indicating greater self-efficacy.
[Time Frame: At W1 (Week 1-4) and W2 (Week 9)]
Self-Efficacy to Engage (SE-E) scale
Time Frame: [Time Frame: At W2 (Week 9)]
Self-Efficacy to Engage (SE-E) will be measured at W2 among participants in the CM group upon access to the intervention, using a previously developed 7-item self-reported scale. The SE-E assesses confidence in engaging with the online intervention and is conceptually aligned with subjective engagement. An example item is: "How confident are you in your current ability to pay close attention when engaging with this online intervention?" Items are rated on a 5-point scale (0 = no confidence to 4 = complete confidence). Although previously developed, the scale was only used in a feasibility trial; thus, reliability and validity will be evaluated prior to hypothesis testing. Total scores range from 0 to 28, with higher scores indicating greater engagement self-efficacy.
[Time Frame: At W2 (Week 9)]
Physical Activity Outcome Expectations (PAOE) scale
Time Frame: [Time Frame: At W1 (Week 1-4), W2 (Week 9), and W3 (Week 13-16)]
Physical Activity Outcome Expectations (PAOE) will be assessed at W1, W2, and W3 using a modified 13-item self-reported scale capturing beliefs about expected outcomes of physical activity (PA). The scale was adapted from the Multidimensional Outcome Expectations for Exercise scale, grounded in social cognitive theory and encompassing physical, social, and self-evaluative domains. Modifications were informed by responses from 30 adults with obesity in a 2025 feasibility trial, using inductive analyses and independent item review to enhance relevance to obesity-specific PA contexts. An example item is: "Physical activity will improve my stamina for daily activities." Items are rated on a 5-point scale (1 = strongly disagree to 5 = strongly agree). Psychometric evaluation will be conducted prior to hypothesis testing. Total scores range from 13 to 65, with higher scores indicating more positive outcome expectations.
[Time Frame: At W1 (Week 1-4), W2 (Week 9), and W3 (Week 13-16)]
Subjective Engagement (SE) scale
Time Frame: [Time Frame: W2 (Week 9)]

Subjective engagement (SE) will be assessed among participants assigned to the CM group after intervention access is provided, using a newly developed subjective engagement scale. This 7-item measure is designed to assess participants' subjective engagement with the web-based intervention, consistent with conceptualizations of engagement in the online behavioral intervention literature. An example item is: "I paid close attention when engaging with this online intervention." Responses will be recorded using a five-point Likert scale (i.e., 0 = not at all to 4 = completely). Because the engagement scale is newly developed, evidence regarding the validity and reliability of scores derived from this measure will be evaluated using data collected at W1.

Total scores range from 0 to 28, with higher scores indicating better outcomes.
[Time Frame: W2 (Week 9)]
Support from Obesity Care Centers for Physical Activity (SOCC) scale
Time Frame: [Time Frame: At W1 (Week 1-4)]
Support from Obesity Care Centers (SOCC) will be assessed at W1 using a 7-item self-reported scale informed by the 2025 CM feasibility trial. The SOCC assesses experiences with and perceptions of physical activity (PA)-related support received outside the CM intervention. It includes a screening item on receipt of PA support, followed by conditional items assessing type of support and satisfaction. Participants reporting support describe it in open-ended form and rate satisfaction on a 5-point scale (1 = very dissatisfied to 5 = very satisfied). Additional items assess referrals to PA resources and perceived preferences, needs, and barriers. Data will be used descriptively to contextualize PA support and inform intervention refinement. Total scores range from 7 to 35, with higher scores indicating greater perceived support.
[Time Frame: At W1 (Week 1-4)]
International Physical Activity Questionnaire-Short Form (IPAQ-SF) scale
Time Frame: [Time Frame: At W1 (Week 1-4) and W3 (Week 13-16)]
Self-reported PA will be measured at W1, W2, and W3 with the short form of International Physical Activity Questionnaire (IPAQ). This questionnaire assesses the frequency and duration of walking, moderate-, and vigorous-intensity PA over the past 7 days. Average minutes per day of moderate-to-vigorous physical activity (MVPA) will be calculated based on the IPAQ guidelines.
[Time Frame: At W1 (Week 1-4) and W3 (Week 13-16)]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Iowa State University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Michigan State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 21, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 28, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 3, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 26-187

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Confident Moves (CM) Intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings